{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:07:48Z","timestamp":1776866868730,"version":"3.51.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Inflammatory bowel disease (IBD) remains a critical unmet medical challenge, with a substantial number of patients experiencing ineffective treatment or therapeutic failure over time. Here, GB20-5A8-31, a novel anti-TNF-like ligand 1A (TL1A) antibody, was engineered for high potency and superior developability. GB20-5A8\u201331 exhibited ultra-high affinity (KD = 5.11\u00d710\u2013\n                    <jats:sup>11<\/jats:sup>\n                    M) for human TL1A, potent inhibition of TL1A signaling\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Meanwhile, GB20-5A8\u201331 demonstrated potent anti-inflammatory effects and anti-fibrotic tendencies in both the 2,4,6-trinitro-benzenesulfonic acid-induced rat and dextran sulfate-induced hTLIA-transgenic mouse acute IBD models. Its favorable pharmacokinetic profile, including an extended half-life (T\n                    <jats:sub>1\/2<\/jats:sub>\n                    = 248.54 h) in hFcRn-transgenic Sprague-Dawley rats, supports sustained target engagement. Crucially, GB20-5A8\u201331 exhibits advantageous biophysical properties\u2014including high stability, solubility, and low aggregation\u2014which facilitate the development of high-concentration formulations aimed at improving patient compliance. In summary, these findings indicate that GB20-5A8\u201331 is a therapeutic candidate for IBD with promising preclinical efficacy and the potential to advance to the Chemistry, Manufacturing and Controls research.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1682346","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:17:23Z","timestamp":1770131843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["GB20-5A8-31, an anti-TL1A antibody for treating inflammatory bowel disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Huang","sequence":"first","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongying","family":"You","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianqi","family":"Yao","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Tong","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Huang","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Chen","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Lu","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiming","family":"Li","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Sciences","place":["Hefei, Anhui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suofu","family":"Qin","sequence":"additional","affiliation":[{"name":"Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41575-023-00854-4","article-title":"Deciphering the different phases of preclinical inflammatory bowel disease","volume":"21","author":"Rudbaek","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000380","article-title":"Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases","volume":"21","author":"Yarur","year":"2015","journal-title":"Inflammatory Bowel Diseases."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in IBD: from pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.005","article-title":"Safety of anti-TNF agents in pregnancy","volume":"148","author":"Felice","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in crohn\u2019s disease and 4 years in ulcerative colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J Crohn\u2019s Colitis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"891328","DOI":"10.3389\/fimmu.2022.891328","article-title":"Role of TL1A in inflammatory autoimmune diseases: A comprehensive review","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.immuni.2018.10.014","article-title":"Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis","volume":"49","author":"Castellanos","year":"2018","journal-title":"Immunity."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4033","article-title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells","volume":"178","author":"Prehn","year":"2007","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.04.037","article-title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation","volume":"135","author":"Takedatsu","year":"2008","journal-title":"Gastroenterology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.3390\/ijms26115017","article-title":"TL1A as a target in inflammatory bowel disease: exploring mechanisms and therapeutic potential","volume":"26","author":"Tettoni","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502466","article-title":"A novel role for TL1A\/DR3 in protection against intestinal injury and infection","volume":"197","author":"Jia","year":"2016","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00583","article-title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A co-stimulatory system of cytokines with diverse functions in gut mucosal immunity","volume":"10","author":"Valatas","year":"2019","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5927064","DOI":"10.1155\/2021\/5927064","article-title":"Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis","volume":"2021","author":"Wenxiu","year":"2021","journal-title":"Mediators Inflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-024-2875-1","article-title":"TL1A promotes fibrogenesis in colonic fibroblasts via the TGF-\u03b21\/smad3 signaling pathway","volume":"44","author":"Song","year":"2024","journal-title":"Curr Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.37","article-title":"Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis","volume":"7","author":"Shih","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: A phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0754","article-title":"P0580 Efficacy and safety results of tulisokibart re-induction treatment in participants with ulcerative colitis in the Phase 2 ARTEMIS-UC clinical trial","volume":"19","author":"Hoque PhD","year":"2025","journal-title":"J Crohn\u2019s Colitis."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0100","article-title":"DOP061 RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis \u2013 Findings from the phase IIb TUSCANY-2 trial","volume":"19","author":"Allegretti","year":"2025","journal-title":"J Crohns Colitis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amsu.2016.07.019","article-title":"The TNBS-induced colitis animal model: An overview","volume":"11","author":"Antoniou","year":"2016","journal-title":"Ann Med Surgery."},{"key":"B29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12906-023-04237-9","article-title":"Shaoyao decoction alleviates TNBS-induced ulcerative colitis by decreasing inflammation and balancing the homeostasis of Th17\/Treg cells","volume":"23","author":"Wu","year":"2023","journal-title":"BMC Complement Med Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human igG1s engineered for enhanced binding to the neonatal fc receptor (FcRn) *","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J Biol Engineering."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume-title":"Lancet Gastroenterol Hepatol","author":"Danese","year":"2025"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","article-title":"OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"B35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0016-5085(89)80079-4","article-title":"Hapten-induced model of chronic inflammation and ulceration in the rat colon","volume":"96","author":"Morris","year":"1989","journal-title":"Gastroenterology."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2015.01.006","article-title":"Experimental models of inflammatory bowel diseases","volume":"1","author":"Kiesler","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatology."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.31","article-title":"Intestinal fibrosis in IBD\u2014a dynamic, multifactorial process","volume":"6","author":"Rieder","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.gastro.2016.09.047","article-title":"Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases","volume":"152","author":"Rieder","year":"2017","journal-title":"Gastroenterology."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1682346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:30:56Z","timestamp":1771925456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1682346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1682346"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1682346","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1682346"}}